Peptide Synthesis Services for CROs: 2026 Guide

Peptide synthesis services for CROs are outsourced sequence design, production, purification, and analytical characterization workflows that let contract research organizations deliver sponsor-defined peptide specifications without carrying in-house synthesis capacity. A CRO's requirements differ from an academic lab's: every batch has to trace back to a written scope, a sponsor protocol, and an audit-ready lot record, and production has to flex from milligram-scale feasibility work to multi-gram supply inside a single project timeline.

TL;DR

Peptide synthesis services for CROs succeed or fail on lot-level documentation, not on advertised turnaround alone.
Scale flexibility matters more than headline price — sponsors move from screening quantities to production runs inside one contract.
Analytical acceptance criteria (identity by mass spec, purity by HPLC) must be agreed with the sponsor before synthesis starts, not after.
Simple Life Science supports custom peptide and small-molecule synthesis with defined specifications and lot documentation for research-only use.

Why peptide synthesis services matter for CROs

A CRO does not buy a peptide. It buys a documented process it can hand to a sponsor's quality or regulatory reviewer. That means the vendor selection decision is really a documentation decision: does the synthesis partner produce a certificate of analysis that matches the sponsor's protocol, and does the lot record survive an audit two years later?

Most CRO peptide programs run in phases — a feasibility batch, a repeat batch for a second study arm, then a scaled batch for extended work. Each phase has its own acceptance criteria, and a vendor that cannot repeat a specification exactly, batch to batch, forces the CRO to re-validate its own study design. That repeat cost is the real reason CROs standardize on one or two synthesis partners instead of shopping every order.

Define the sponsor's specification and acceptance criteria

Before any synthesis order goes out, the CRO needs the specification in writing — sequence, modifications, purity threshold, quantity, and format (salt form, lyophilized versus solution).

Confirm sequence and any non-standard modifications (acetylation, amidation, non-natural residues) in writing with the sponsor
Set the purity acceptance threshold explicitly; ≥95% purity by HPLC is a common baseline for research-grade peptide batches
Specify identity confirmation method (typically mass spectrometry) as part of the acceptance criteria, not as an optional add-on
Record quantity and format requirements (lyophilized powder, salt form, counter-ion) before quoting
Flag any study-specific stability or storage requirement the vendor needs to accommodate

Select synthesis scale and chemistry route

Scale drives method choice. A 5 mg feasibility batch and a 2-gram production batch are different jobs even when the sequence is identical.

Match chemistry route (solid-phase, hybrid, or fragment condensation) to sequence length and modification complexity
Confirm the vendor can run both screening-scale and scale-up batches without switching processes mid-project
Review peptide synthesis services ranked by production scale before committing a multi-phase contract to one vendor
Ask how a scale change affects lead time and whether the acceptance criteria carry over unchanged
Confirm capacity for difficult sequences (high hydrophobicity, aggregation-prone segments) before quoting a full program

Plan purification and analytical testing

Purification method and analytical review have to be locked before production, not negotiated after the batch is made.

Define the purification method (reverse-phase HPLC is standard for research peptides) and target purity band
Specify which analytical tests accompany every lot: identity, purity, and — where relevant — counter-ion content or residual solvent
Compare analytical testing services for peptide purity to confirm the method matches what the sponsor protocol requires
Require a certificate of analysis with every lot, not on request
Set a retest trigger (time-based or event-based) for batches held in inventory across a multi-arm study

Qualify a synthesis partner for CRO project pipelines

Once scope, scale, and acceptance criteria are defined, the CRO is choosing a partner it can reuse across projects — not a one-time vendor.

Request a written scope document per project, not a generic quote
Confirm the vendor issues lot-level documentation as standard, including batch-specific analytical data
Check custom peptide synthesis services ranked by price to understand where different vendor tiers sit before a full RFP
Ask directly whether the vendor supports both research peptide orders and small-molecule synthesis, since many CRO programs need both
Simple Life Science works from a defined scope through synthesis, purification, and analytical characterization for research-only projects, which keeps documentation consistent across a CRO's project queue

Verify identity and purity before release

Release decisions belong to the CRO, not the synthesis vendor — verification is a separate step from production.

Cross-check the certificate of analysis against the original written specification line by line
Confirm identity data (mass spec result) matches expected mass within the agreed tolerance
Confirm purity data meets the pre-agreed threshold, not a vendor default
Hold release until documentation is complete; a missing analytical field is a reason to delay, not to waive
Log any deviation and its resolution as part of the project record

Document lot records for audit readiness

Sponsor audits happen months or years after a batch ships. The record has to stand on its own.

Retain the written scope, certificate of analysis, and any correspondence on specification changes in one project file
Confirm lot numbers on internal records match the vendor's lot numbers exactly
Store analytical raw data references (chromatograms, spectra) alongside the summary certificate where the vendor provides them
Track which sponsor protocol version each batch was produced against
Keep documentation retention aligned to the sponsor's study timeline, not just the CRO's internal policy

Manage retesting and reorder timing across projects

Multi-project CRO queues mean the same peptide may sit in inventory while a second study arm is scheduled.

Set a retest interval for stored lyophilized inventory rather than assuming indefinite stability
Confirm reconstitution and storage guidance with the vendor before a batch is pulled for a new study arm
Reorder against the original specification rather than a new quote, to avoid lot-to-lot drift
Flag any sequence or scale change to the vendor explicitly — a reorder is not automatically identical to the original batch

Submit a scientific brief for review

Send your specification for synthesis and documentation review.

Submit a brief

Comparison: synthesis options for CRO programs

Option	Best for	Key limitation
In-house synthesis line	CROs with sustained, high-volume peptide programs and capital budget	Capex and validation timeline before first batch
Academic core facility	Early feasibility screening on a single sequence	Limited lot documentation depth for sponsor audits
Boutique custom synthesis vendor (e.g., Simple Life Science)	Project-based sponsor work needing lot-level documentation across scales	Capacity ceiling on very large single-batch runs
Large CDMO	Late-stage programs needing full regulatory-grade support	Longer lead times and higher minimum commitments

Verdict: for project-based CRO work that needs to move between screening scale and scale-up without losing documentation continuity, a boutique custom synthesis vendor with defined lot records is the practical fit; reserve large CDMOs for late-stage programs with regulatory support requirements.

Common mistakes CROs make with peptide synthesis vendors

Treating vendors as interchangeable. A lower quote with thinner documentation costs more in re-validation time than it saves.
Locking acceptance criteria after production starts. Purity and identity thresholds have to be agreed in the written scope, not renegotiated on delivery.
Underestimating retest timing. Inventory held between study arms needs a retest trigger, not an assumption of indefinite stability.
Choosing on turnaround alone. A fast quote with no analytical method disclosure is a documentation gap waiting to surface at audit.
Ignoring scale flexibility. Committing a multi-phase contract to a vendor that only handles one production scale forces a mid-project vendor switch.

FAQ

What documentation should a CRO expect with every peptide batch?

A CRO should expect a certificate of analysis covering identity (typically mass spectrometry) and purity (typically HPLC) for every lot, tied to a written scope document. Lot numbers on the certificate should match the vendor’s internal batch record exactly.

Is peptide synthesis for CROs different from synthesis for academic labs?

Yes — CRO work is tied to sponsor protocols and audit trails, so documentation depth and batch-to-batch consistency matter more than for exploratory academic screening. Academic core facilities often skip the lot-level detail CRO sponsors require.

What purity threshold is standard for research peptides in 2026?

A purity threshold of 95% or higher by HPLC is a common baseline for research-grade peptide batches in 2026, though the sponsor protocol sets the exact figure per project. The acceptance criterion should be written into the specification before synthesis starts.

Can one vendor handle both screening-scale and production-scale batches?

Some vendors support both, which avoids switching processes mid-project. Confirm scale flexibility and whether acceptance criteria carry over unchanged before committing a multi-phase contract to one supplier.

How often should stored peptide inventory be retested?

There is no universal interval — it depends on storage condition, formulation, and the sponsor’s study timeline. Set a retest trigger as part of the project plan rather than assuming indefinite shelf stability.

Does Simple Life Science support custom peptide synthesis for CRO projects?

Simple Life Science works from a defined scope through synthesis, purification, and analytical characterization for research-only projects, producing lot-level documentation suited to CRO project files.

What is the difference between bulk peptide API and custom synthesis for a CRO?

Bulk peptide API supplies an existing, defined sequence at scale, while custom synthesis covers sequence design and production for a project-specific peptide or small molecule. CRO programs often need both across a study lifecycle.

Why does scale flexibility matter more than price for CRO synthesis vendors?

CRO contracts frequently move from a milligram-scale feasibility batch to a gram-scale production batch inside one program. A vendor that cannot repeat the same specification across scales forces a mid-project vendor switch and re-validation cost.

One last thing

The single biggest documentation gap in CRO peptide programs is not missing purity data — it is a mismatch between the sponsor's protocol version and the lot record on file. A batch produced against an earlier draft of the specification, without a documented change log, is the finding an auditor catches first. Build the change log into the project file from the first batch, not after a second study arm is added in 2026.